Research and references
Key research and evidence relating to anticholinergic burden and clinical practice
Assessing anticholinergic burden
Reference | Summary |
The Royal Australian College of General Practitioners (RACGP) | This clinical resource focuses on providing appropriate care for older people. Part A. Deprescribing
Part A. Medication management Part A. Polypharmacy Part A. Behavioural and psychological symptoms of dementia
Part A. Short-term pharmacotherapy management of severe BPSD
Part A. Pain
Part A. Mental health
Part A. Falls
Part A. Urinary incontinence |
Kouladjian O’Donnell et al. 2017 | This article provides health professionals with information about older-aged people and the pharmacology of medicines with anticholinergic effects. The definition, measurement and poor outcomes of anticholinergic burden are also discussed, and interventions to reduce anticholinergic burden, including deprescribing. The authors of the article include Professor Sarah Hilmer and Dr Lisa Kouladjian O'Donnell. |
Bell et al. 2021 | This article published by Prescriber, a UK-based publication, provides information for health professionals about medicines with anticholinergic effects, measurement scales for anticholinergic burden and clinical practice guidance for GPs and pharmacists. |
Kalisch Ellet et al. 2014 Multiple anticholinergic medication use and risk of hospital admission for confusion or dementia | This cohort study of 36,015 Australian veterans identified an association between the use of multiple medicines with anticholinergic effects and the rate of hospitalisation due to confusion and dementia, with an IRR of:
|
Patient-centred care
Reference | Summary |
Stewart et al. 2021 Barriers and facilitators to reducing anticholinergic burden: a qualitative systemic review | A systematic review of studies exploring barriers and facilitators to reducing anticholinergic burden in the Australian healthcare system. It found that studies exploring patient and carer perspectives are currently absent but are required to ensure person-centred care and feasibility of future interventions. |
Weir et al. 2020 | This Australian study highlights the barriers to an effective Home Medicines Review (HMR), including gaps in inter-professional communication and factors relating to patient involvement, such as limited medicines understanding and health literacy. |
White et al. 2012 Consumer perspectives of the Australian Home Medicines Review program: benefits and barriers | This study investigates Australian patients’ perceived benefits and barriers regarding HMRs from 14 focus groups. It concluded that promotion of HMRs would increase patient uptake, and communicating the process/benefits clearly and sensitively would obviate consumer misconceptions and/or barriers. |
Managing anticholinergic burden
Reference | Summary |
Manger. 2019 | This article, published in the Australian Journal of General Practice (AJGP), provides a concise update regarding the evidence-based clinical lifestyle interventions in the management of both mental illnesses and the physical chronic diseases highly prevalent in people with mental illness. |
Bell et al. 2012 Anticholinergic and sedative medicines – prescribing considerations for people with dementia | This article, published in the Australian Family Physician, examines the clinical considerations associated with using anticholinergic and sedative medicines in people with dementia or incipient cognitive impairment. |